Key points from article :
A new €100 million investment fund, naturalX Health Ventures, has been launched to boost consumer health innovation in Europe. The fund aims to shift healthcare from a reactive to a proactive model, emphasizing prevention and self-management. It is the first dedicated consumer health investment fund in Europe, addressing what its founders see as a fragmented and underfunded sector compared to the US.
Founded by German entrepreneur Marvin Amberg in partnership with plant-based pharmaceutical company Schwabe Group, naturalX seeks to bridge the funding gap for European startups in consumer health. The firm believes Europe is at a turning point, with growing consumer interest in science-backed wellness solutions. Despite successful companies like Oura and Neko Health, many startups struggle to secure investment to scale.
naturalX focuses on proactive health solutions, including sleep, gut health, prevention, and longevity. It primarily invests in Series-A funding rounds, with initial investments ranging from €3-5 million and up to €10 million per company. Over the past 18 months, the fund has already backed companies like mybacs, Flow Neuroscience, Kyan Health, and Meela, as well as other health-focused venture capital funds. Now, it is expanding its investment team and seeking new partnerships to drive the future of consumer health in Europe.
